OCULAR THERAPEUTIX INC. - COMMON STOCK

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

09 апр 2024 06:30:00 Источник Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

06 апр 2024 09:00:00 Источник Nasdaq GlobeNewswire

Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)

26 мар 2024 06:30:00 Источник Nasdaq GlobeNewswire

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results

11 мар 2024 15:05:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

06 мар 2024 09:53:23 Источник NetDania Notify

Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024

05 мар 2024 06:30:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

04 мар 2024 08:45:09 Источник NetDania Notify

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

01 мар 2024 11:02:47 Источник NetDania Notify

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

26 фев 2024 08:47:12 Источник NetDania Notify

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

23 фев 2024 09:33:55 Источник NetDania Notify

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

22 фев 2024 08:45:24 Источник NetDania Notify

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer

22 фев 2024 06:32:00 Источник Nasdaq GlobeNewswire

Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement

22 фев 2024 06:31:00 Источник Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Board of Directors and Leadership Updates

22 фев 2024 06:30:00 Источник Nasdaq GlobeNewswire

Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer

15 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

13 фев 2024 06:38:24 Источник Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

25 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

18 дек 2023 15:01:00 Источник Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock

13 дек 2023 21:09:58 Источник Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock

13 дек 2023 15:01:11 Источник Nasdaq GlobeNewswire